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Abstract  
 The current speed of economic growth has greatly affected the means of pharmaceutical 
organizational operations in the establishment of clinical trials. Pharmaceutical organizations are 
looking for ways to increase customer experience and reduce costs of production in the process. 
The customer experiences can be increased by creating a forum for active participation during 
the processes of the establishment. Equally, the costs of production and conducting research 
study can be ensured through the reduction of reworking chances. Through the creation of this 
experience, the effectiveness of the clinical trials needs to be properly created. Traditionally, 
organizations used waterfall methodology in the development of the clinical trials. The linear 
processes did not allow for proper correction of the processes and how the customers could 
understand the progress unless the developments were at certain milestones. The system of 
operation is still in use today because of the strong traditional background. As a result, 
organizations are forced to rework certain operations because of the reduced client satisfaction. 
These reworks force the organizations to spend more on the processes hence reducing the 
effectiveness of the processes. The introduction of the agile methodology has played a crucial 
role in the development of cost effective and efficient processes of clinical trials. This paper 
proposes the effectiveness of agile methodology in the establishment of clinical trials.  
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Chapter One: INTRODUCTION 
Background of Research 
Agile framework for software development, including the Scrum structure, have become 
universal since the 2001 Declaration for Agile Software Development. Many organizations, for 
example, Amazon, Yahoo, Marriott, and even SAS have exhibited the progressive effect of Agile 
on data innovation development and usage. Inside the government, the Government 
Accountability Office (GAO) in a multi-office contemplate recognized particular development of 
Agile as a best practice, while offices including the Federal Bureau of Investigation (FBI) and 
the Department of Defense (DoD), Department of Veterans Affairs, Department of Homeland 
Security (DHS), and others have approved the part of Agile in emphatically changing upcoming 
and innovative short IT projections (Azanha, Argoud, Camargo Junior & Antoniolli, 2017).  
While the advantages of Agile are clear and persuading, its application and selection over 
the product development group have not been without inclination. Agile-related terminology, 
preparing, writing, and business postings regularly delineate a romanticized "developer" original 
who codes unremittingly in at least one object-oriented programming (OOP) dialects, whose 
value is estimated by the product he makes, and who might possibly have an undesirable 
dependence on Zombie-related legend, legend, and eBay barters. Truly, programming engineers 
and developers speak to a significantly more extensive fragment and incorporate many experts 
who will not grasp the developer group or title. Biostatisticians, factual developers, information 
examiners, monetary investigators, clinical analysts, information scientists, doctors, clinicians, 
and a wealth of different experts rather regularly see programming development not as endpoint, 
but instead as a way keeping that in mind-an instrument to help the observational journey for 
truth (Rauchenberger, Little & Montana, 2013).  
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Along these lines, these experts while containing both essential and auxiliary developer 
parts  might be more unconvincing than supposed traditional developers to incline toward the 
product driven, pointlessly limit clarifications of Agile that sadly continue. Since SAS 
developers optimize such a various cluster of parts in similarly assorted associations and 
ventures, they frequently get business value not from code they make but instead from 
subordinate information items - including informational collections, investigations, systematic 
reports, and information driven choices.  
Acquired from the Software Industry, Agile Product Development Methodology holds 
incredible guarantee for use in Adaptive Clinical Study Development (Aziz & Abdullah, 2015). 
Agile, is best portrayed as having two essential properties—soundness and dynamism, that 
enables associations to react and quickly adjust to changes in the earth. Accordingly, Agile tries 
to standardize three basic transformative standards, the 3 E's that applies to associations and 
venture management association inside them (Aziz & Abdullah, 2015).  The first E is 
envisioning; which includes making noteworthy, straightforward, and key direction concentrated 
on partner fulfilment, empowered by solid sponsorship at the basic levels in the association. The 
second E is engaged; which entail making groups with a common reason and vision, an end to 
end responsibility and a feeling of proprietorship; as well as to create a culture that empowers 
group interdependency. The third E is empowering, which involves   characterizing clear, level 
structures/parts, consider vigorous groups of training, energize dynamic association, give cutting 
edge innovation bolster, and release the creative soul (Aziz & Abdullah, 2015). These three basic 
standards empower agile preparation inside associations, and thusly, help set the foundational 
structure for venture management workplaces to help agile undertakings. In this regard, the aim 
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of the current study is to examine the agile methodology to define its feature and relate them to 
applications in the clinical trials area of research.  
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Problem Statement 
The modern society has been undergoing significant changes due to the economic, social 
and technological advancements. In the business scope, customers are demanding better services 
and efficiency, and organizations are competing in a position of better efficiency and value for 
customers (Kettunen, 2017). All these dynamics are based on the pursuit of reducing costs while 
optimizing quality and efficiency. For company teams to deliver high levels of customer value, 
they utilize various project management and implementation tools, with the traditional one being 
the waterfall methodology.  
Before the introduction of agile methodology, the waterfall methodology had the widest 
application. This methodology cost more because of the sequential way of handling the processes 
which had to be followed for its effectiveness. The waterfall methodology is characterized by 
sequential and overlapping phases that are linked to one another. The defined method of 
operations made the process more expensive. Equally, the testing points of the waterfall 
methodology were in the later stages. From this development, it becomes hard to make changes 
during the stages of application.  
Clinical trials need that the stakeholders get a chance to evaluate the product before the 
actual mass production. Unfortunately, the current methodology allows for testing only in late 
stages of development because of this overall development increases the overhead costs and time 
for the development. In the current methodology, the stakeholders are denied the chance to make 
their evaluations and only to hope that the product will come out fine at the point of testing. The 
costs become high when there is a fault in a product. The product must be redone, and more time 
is spent on one product.  
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More recently in 2001, the agile methodology was introduced, and although it has not 
found universal applications, it remains an attractive methodology, which many agencies have 
already adopted (Juricek, 2014).  In the clinical research, the researchers and scientists are 
working to optimize processes, such as drug development and medical devices design and 
development. The clinical trials on drugs and equipment, as well as IT tools such as programs 
also need improved levels of efficiency, to cut costs and complete the projects more efficiently. 
The present situation is that the clinical trials can benefit from agile methodologies if it is more 
efficient and applicable.  
However, the reality is that there are many inefficiencies in the clinical trials, which lead 
to many of the trials failing. On this note, it is assumed in the current study that the agile 
methodology could have beneficial features which can benefit the clinical trials (Azanha et al., 
2017). It is on that note that the present investigation set out to examine the agile methodology of 
research and project management, to define its features in view of the waterfall or traditional 
approaches in the application and determine if it is applicable and beneficial to the clinical trials.  
On that note, the underlying question answered is: can the agile methodology be applied in the 
clinical trials domain to boost efficiency and, performance and cost-effectiveness?  
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Project management Justification 
Adopting a clinical trial is a project. This is because there is an initiation, where the 
current systems are studied and marked. Then there is planning. This is the stage where adequate 
plans are laid in place on how to adopt new systems, and ensure the agile methodology is 
adopted in clinical trials. In the execution phase, the real plans are implemented, and tested to 
ensure that they work. Then there is closure where the systems will have been tested, and if 
found advantageous, the process is closed. By having all these components, then this qualifies as 
a project.  
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Literature Review 
Clinical trials are very complex especially when it comes to the need to reduce time and 
cost. The clinical trials must be done through multidisciplinary teams and within the required 
times. The economic situations keep fluctuating and because of this, there is a need to come up 
with the most economic and effective approach in the development of clinical products. The 
processes through which the products are made are determined through the quality of the 
product, the reliability, safety and the efficiency of the processes used. As clinical trials need to 
make some of the highest quality products in the market today, the current selection of approach 
is based on the historical views of the product development. Agile methodology is one of the 
latest concepts in the clinical trials and because of the benefits linked to the methods; its 
implementation process needs to be hastened. As different organizations focus on waterfall 
methodology, this section relies on the previous research works done on the agile methodology. 
The section is divided into a couple of topics based on the findings of the researchers.  
Palmquist et al., (2013) established that traditionally, clinical systems established 
randomization process to help in randomly allocating patients to a trial. As the methods 
progressed, the clinical trials established the application of electronically supported plan models 
and this model was perfected using the conventional waterfall method. With the use of this 
model, after the product had successfully gone through the first stage of development, it would 
automatically go to the second stage. Through this establishment, it has been hard for an error 
created in the first step to be addressed. Because of this difficulty, there is a need for the clinical 
trials to embrace the introduction of the agile methodology because of the flexibility in 
application.  
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Development of high quality clinical trial software (CTS) 
Serrador & Pinto, (2015) believes agile methodology is crucial in the reduction of time 
spent during the development of the clinical product. In this research, it was equally proven that 
the methodology does not only come up with ways of reducing the time spent on the 
development but the sustainability of the processes play an important role. Through this 
methodology, high quality clinical trial software is salient. Through this software, the agile 
methodology works within a system that has a proper budget. Unlike the waterfall methodology, 
the clinical trial software that comes with an agile methodology is crucial because its application 
does not require additional resources (Serrador & Pinto, 2015). For example, the steps that are 
involved in product development using the methodology can be corrected without having to skip 
the least of them. As the first step leads to another, the faults in the product can be seen. The 
corrections are ensured when the product is in the process and from this advantage; there is a 
reduction in the chances of rework.  
For clinical trials, the accuracy of the collected data is salient. The development of the 
drugs through these experimental designs requires data accuracy so that the recurrence of the 
problems may be prevented. The clinical trial software used in the agile methodology developed 
a properly designed study protocol. Clinical trials come with trial questions which need to be 
answered. From the development of the questions, the variables and the measures of the products 
to be developed are created. The accuracy and the quality of the determined results are dependent 
on the quality of data to be collected for the trial. The software plays an important role in 
managing the data and this is an aspect that is not addressed in the waterfall methodology. In the 
normal process of data analysis, a lot of time is spent in the process. When the given data is not 
accurate, the whole process becomes futile (Thiemich & Puhlmann, 2013). The inaccuracy of the 
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data would lead to time wastage. This problem is addressed by agile methodology through the 
application of clinical trial software. The errors that enter the database are minimized and the 
management of the data is increased.  
Reduced waiting time between steps 
The study protocol design needs a couple of steps for an effective development of 
products. Each step needs distinct roles within the establishment. In agile methodology, the steps 
between the product developments are done in a quicker way. The product moves from one step 
to another at a comparatively faster rate than in waterfall methodology. Because of the 
accompanying technology in agile methodology, the assessment of the products tends to be faster 
(Thiemich & Puhlmann, 2013). The stakeholders in an organization using waterfall methodology 
will have to spend more time in examining the quality of the products at each step of 
development. More time is spent in the micromanagement of the protocol designs and this makes 
waterfall methodology less efficient especially when it comes to time (Thiemich & Puhlmann, 
2013). Agile methodology on the other hand does not focus on the micromanagement of the 
protocols but the research team can focus more on the means of solving specific problems 
instead.  
The agile methodology focuses on the establishment of flexible and stable systems which 
can be sustainable in the clinical trials. The methodology is characterized by time-boxed 
iterations. The time boxed iterations create a dependable system which can support both adaptive 
planning and evolutionary delivery (Serrador& Pinto, 2015). Clinical trials usually have certain 
rapid changes and needs for alterations. The fact that these changes are rapid creates the need for 
a stable and supportive system that can adjust to these requirements without an alteration on the 
expected delivery time. Agile methodology has technologies that encourage both flexible and 
13 
APPLYING THE AGILE MECHANISM IN THE CLINICAL TRIALS DOMAIN 
rapid responses towards the needed alterations. The efficiency of the operations is measured 
based on the time of production and the delivery.  
Rauchenberger, Little & Montana, (2013) confirm that in the traditional manufacturing 
systems, organizations depended on steps for effective follow up on the quality of the product. 
Waterfall methodology provided a way through which the defection of the product could be 
traced to a step of operations. As the system led to proper product development, the duration of 
coverage was longer. The current pharmaceutical industries still trust in the waterfall 
methodology for the development of the pharmaceutical products. Both in the traditional and 
modern manufacturing means, the steps were to be completed sequentially. The processes were 
developed at the expense of time. The numbers of steps are to be determined before the 
processes are initiated so that the sequence can be followed during the manufacturing process. 
This methodology consumed a lot of time and the numbers of products to be manufactured were 
greatly reduced.  
For a clinical study, Mahadevan, Kettinger&Meservy, (2015) opines that the duration for 
completing a project is shorter. From this research, it was established that a project that can take 
eight weeks to be completed using a waterfall methodology could only take five weeks on agile. 
This difference is created from the steps used in the process.  
Consistency in communication and updates 
Lodha, (2016) established that in as much as there are several organizations using 
waterfall methodology in their clinical trials. Very few have come to the realization of the 
accompanying shortcomings. Some of the organizations that have noticed the shortcomings of 
the methodology are shifting from its application. The waterfall methodology offers a linear 
14 
APPLYING THE AGILE MECHANISM IN THE CLINICAL TRIALS DOMAIN 
means of communication. There is no chance of check-ins that can be done by the patients or 
other stakeholders. The possibility of adjusting is controlled at specific milestones and this 
reduces the chances of effectiveness. The methodology depends more on the hope of quality 
rather than assurance. The communication signals can only be gathered at the milestones 
developed by the methodology and this created a huge gap in its application.  
Glaiel, Moulton & Madnick, (2014) furthered the study on the importance of 
communication in agile methodology. As opposed to the waterfall methodology, agile creates an 
understanding of communication before the commencement of the project. The agile 
methodology reduces the chances of redesigning the product because of the ease in 
communicating with the established technologies such as the clinical trial software. The 
methodology creates a check in tracking progress where the quality of operation can be tracked 
and, therefore, reducing the chances of rework. The communication channels are created 
sequentially so that when there is an adjustment to be made, the rates of success become higher.  
Newer projects and designs require creativity which enhances the communication 
between team members towards achieving the desire goals (Vijayasarathy& Butler, 2016). Agile 
methodology is not designed specifically. After the methodology has been understood, it 
becomes easy for different clinical trials to be established. The data to be used is not specific. 
Because of this flexibility, organizations can create some of the best practices in the clinical 
trials. The fact that the output is constantly reviewed during the production processes improves 
the chances of correction and this creates a good relationship between the product to be 
developed and the developer. The methodology allows for prioritization at any stage of 
development and this makes it easy for the final product to be of a very high quality.  
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Standardization of the protocols 
Mahalakshmi&Sundararajan, (2013) established that patients have different needs and 
expectations. The clinical trials have different focuses which should be attained. During clinical 
trials, the focuses of the trials are diverse. The methodology allows for easier development of 
standardization protocols. Within a uniform clinical trial or a study, patients have diverse needs 
and expectations. The agile methodology allows for the standardization of the methods, but it 
allows for creating differences so that too much customization can be avoided. The agile 
approach makes it easy for the standardization of the protocols. Standardization, in this case, 
includes the creation of a common system that can be used by all patients. In such a case, it 
would be hard to determine the needs of a specific clinical trial (Mahalakshmi&Sundararajan, 
2013). The agile methodology creates a solution to this barrier by allowing for flexible 
adjustments of the method. At the same time, the methodology allows for a controlling 
mechanism such that the flexibility cannot be designed for a specific clinical trial hence blocking 
out the other possible study tests.  
Changing consumer responsibilities 
Moniruzzaman&Hossain, (2013) claims that to be able to understand the effectiveness of 
agile standardization, understanding the influence of the methodology on how the roles of 
consumer responsibilities are affected is crucial. This concept can be easily understood if the 
responsibilities of the consumers are considered alongside the expectations in a waterfall 
methodology. Firstly, a single individual can play a pivotal role in the creation of a link between 
the development team and the organization. In most cases, clinical trials have a couple of tests 
and studies involved. In these studies, how the programs are handled should be understood by 
the patients and the consumers of any form. The organizations need a link between the 
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production processes and the operations of the entire company. The creation of this link explains 
the concept of standardization as there are different products that can be accomplished using the 
same processes.  
The agile methodology creates an opportunity for specificity. As the methodology allows 
for product or processes standardization, the consumers can be involved in the process 
(Palmquist et al., 2013). The involvement of the patients in the processes improves the 
developmental processes of the product and the chances to make mistakes are reduced in the 
process. The inclusion of the customers in the process of clinical trials should not be 
underestimated as through this process, it would become easy not to redo a task that had been 
done. The patients can see the progressive development of the processes and this improves the 
chances of improvements in the successive stages. The iterative nature of agile methodology 
makes it easy for the development of a proper product (Moniruzzaman&Hossain, 2013). One of 
the major advantages of agile methodology is that fact that the process of a clinical trial can be 
altered in the duration of the development. The product can be altered during the processes. The 
clients can find it easy to make their preferences at each stage and this is the importance of the 
existing flexibility.  
Patwardhan et al., (2016) opined that for the agile methodology to be successful, 
progressive feedback is necessary. Through this feedback, the development of the product can be 
corrected or improved if there is a need. Because agile methodology allows for iterative 
improvements, coming up with ways of increasing the nature of the product is easy. This is one 
of the reasons why the agile methodology is cost effective especially in the current economy. 
The clients can give their feedbacks at each stage of development and as a result, an appropriate 
method can be established. Waterfall methodology only allows for improvements at specific 
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milestones. A client cannot change the preferences after the process has started. This stiffness in 
the application of waterfall methodology makes it less attractive for flexible processes. Being 
that the approach has been used for ages because of the norms of the organizations, it has 
become hard for the effective development of flexible products over the years. There are times 
when clinical trials require flexibility and adjustments. These adjustments can easily be made 
through agile methodology and, therefore, making it possible for organizations to attract more 
clients (Patwardhan et al., 2016). The involvement of the patients in the processes increases their 
trust hence establishing a means for higher profitability. Equally, this establishment makes the 
customers be available at the right time. as compared to the traditional waterfall methodology, 
clients do not need to appear only at the end of the product, but the involvement will allow for 
continued processes and client participation.  
Agile methodology and cost effectiveness 
The introduction of agile methodology has largely influenced the clinical trials. These 
influences can be linked to the cost reduction and effectiveness of the processes Kettunen, 2(017) 
confirms that all the occurrences in an organization are directed towards the reduction of costs of 
production. When the costs are high, the value of the products would be high and the chances of 
making proper profits are reduced. The means through which agile methodology has influenced 
the cost of production has placed its advantage at a higher level.  
Agile methodology is faster, and this is an aspect of cost effectiveness. When the process 
is faster, a large volume of clinical trials can be ensured. Clinical trials require faster 
developments so that a large volume of products can be affected. The waterfall approach is 
expensive because when a product is faulty, it can only be detected at specific milestones. 
Correcting the product would mean that it must be taken through several processes back 
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(Kettunen, 2017). Such inconveniences cause difficulty in financial planning as they lead to 
higher production costs.  
Clinical trials require quality research with small data developments. For example, when 
a new medical product is to be developed, the sample to be used is just small. The 
standardization of the research requires that each patient should have specific data and 
information that is customized to them. In as much as agile methodology prevents intensive 
chances of customizing data, it allows personalization of information especially when a data 
sample is a small group (Losada et al., 2013). For clinical trials, the aspect of smaller data is 
crucial. It is easier for smaller data to be used with agile methodology because of the progressive 
inspection. It is cheaper to use smaller data because the chances of errors are reduced 
(Papadopoulos, 2015). Waterfall methodology is appropriate for large projects which require 
reduced accuracy in the analysis. Because of the accuracy of smaller data, the agile methodology 
reduces the chances of mistakes as the data is protected and properly analyzed in the process.  
Stoica, Mircea & Ghilic, (2013) confirm that traditionally, the waterfall methodology 
focused on the expectations of the stakeholders. The customers could only see their products at 
certain milestones. In case the clients were not satisfied with the quality of the developed 
product, the organization had to incur extra costs to correct the systems. The satisfaction of the 
clients was uncertain, and, in several cases, additional costs would be incurred in the process. 
Agile methodology has brought about a process that focuses on the needs of the clients 
(Palmquist et al., 2013). The clinical trials are done with the customer in mind. Because of the 
flexibility of the operations, organizations that do clinical tests can invite different clients for 
process confirmation. This allowance makes it easier for the clients to come in and make certain 
adjustments (Saltz, 2015). In these adjustments, the involvement of the clients minimizes the 
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chances of reworking hence saving on the operational costs. Certain defects can be corrected at 
the early stages of the processes hence saving on costs. The involvement of the clients makes it 
easy to satisfy their needs hence saving on the correction costs.  
In the normal project management triangle used in waterfall methodology, the focus of 
the operations involves time, cost and scope. Cost is a factor of time. from the project 
management triangle, the cost of a product was determined by the length of time taken in its 
production (Lotz, 2013). Through this understanding, clinical trials used to take longer and cost 
higher in the process. This triangle opened an avenue for making more profits from simple tests. 
The introduction of agile methodology came with a different triangle of project management. In 
this triangle, the focuses of operation are on value, quality and constraints. The costs of the 
operations and the clinical trials are determined by the quality of the final product. When the 
quality is low, the costs are high because the product must be done again (Papadopoulos, 2015). 
The agile methodology makes the process flexible since the costs of operation are reduced. The 
quality is the focus of production and the chances of the clients being satisfied are very high.  
Rahman, Rutz & Akhter, (2013) believe agile methodology reduces the risks that are 
linked to production. This is so because the approach first reduces the volume of production. 
When the volume is low, the risks that are linked to the cost of production are low. The 
involvement of the clients in the production processes reduces the chances of making mistakes 
during the clinical trial processes. Different organizations have various trials of focus. The trials 
are varied and depending on the client, the involvement would save a lot of resources in the 
process. The risk of rejection is reduced to nil. The products are released to the clients in small 
quantities but early enough. Being that clinical trials only require smaller data, chances of errors 
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are reduced. The costs of doing the clinical trials are equally reduced and this makes agile 
methodology appropriate in the processes of clinical trials.  
The effectiveness of the Agile framework 
Vijayasarathy & Butler (2016) established that agile technology has made it easier for 
smaller teams to come up with very large projects and ensure that they are effectively managed. 
Big projects require big teams for considerations. When the teams are smaller, it became hard for 
the organizations to work with smaller groups in the process of wanting to clear them. Clinical 
domains are very complex to deal with. When there are complications in the process of research, 
it becomes hard for the for the teams to work on them. Bigger teams were preferred to work on 
the projects so that there would be better delivery processes. With this approach, clinical domain 
projects used to be handled but their effectiveness was not guaranteed. The large numbers of the 
professionals handling the projects are usually less effective because of constant problems and 
disagreements. Through the agile methodology, smaller and more efficient groups can be easily 
used in the processes of clinical tests and the results would be much better and more efficient in 
the end. The agile methodology makes the work of the teams easier and the quality of delivery is 
high in the process. The technology equally ensures that the teams are given the opportunity to 
work together under the guidance of operational principles that would place them on course.  
Most projects in clinical trials are long term. Mahadevan, Kettinger, & Meservy (2015) 
established that trials and domains can take a duration of between six to eight months of testing. 
The duration is linked to the fact that the testing durations must be involved with the processes of 
prediction and requirement addition so that there can be ease in operation. Using agile 
technology, Mahadevan, Kettinger, & Meservy (2015) believed projects that could take eight 
months can be done in only four weeks and very effectively. The agile methodology uses a 
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technology called the iterations of ideations. In this technology, the processes involved with the 
product development are deeply considered. The testing durations are reduced, and the processes 
are made to be worked with shorter times which can be easily handled. Agile methodology 
equally uses the processes of coding, iteration and testing which are done as the processes are 
established to create effectiveness in the product quality. The development cycle as created by 
the agile technology ensures that time is saved. The methodology focuses on the aspects of time 
and quality so that there can be a balance between the two. Clinical domains can be handled in a 
faster way with the highest quality of operation. The efficiency of time in the operations of the 
technology does not affect the quality of operations. The processes are made more efficient to up 
to more than 25% and this confirms the effectiveness of the process(Kettunen, 2017).  
Vijayasarathy & Butler (2016) opined that humans are prone to mistakes in different 
projects and these cannot be avoided. The fact that humans make mistakes makes it hard for the 
project developments to be effective. In waterfall methodology, when the mistakes are made, it 
becomes hard for the projects to be continued. The mistakes affect the developments of the 
projects and as a result, it becomes an impossibility to ensure that there is a high quality process. 
With this ideology, the chances of ensuring that the quality of clinical processes is maintained 
are slim. The agile technology allows for corrections of these mistakes during the processes of 
the establishment. There are a couple of things that can be changed especially when they happen 
as mistakes,but the changes can be effectively made in the development cycle and the processes 
are made better. Vijayasarathy & Butler (2016)established that agile methodology has a 
provision of teams where there is a frequent inspection of the processes and this allows for 
changes to be made in the development cycle. The processes are aimed at minimizing the cost of 
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productivity. Wastes are equally minimized with the same processes since they defect of clinical 
trials would be realized before they affect the quality of the trials.  
According to Papadopoulos (2015), the agile methodology provides for engagement of 
the stakeholders and this reduces the chances of dissatisfaction in the processes. Clinical trials 
are always unique. The qualities of operations are necessary, and they need to be very high for 
the effectiveness of the developments. To ensure that there is a high quality, the specifications of 
the stakeholders must be held to a higher degree. The clinical trials are based on the requirements 
and the adherence to the specifications this ensures that the project team and the stakeholders 
collaborate in an appropriate way. Through this collaboration, it becomes easy for the for the 
trials to avoid unnecessary corrections. The corrections that are avoided come with the reduction 
in the costs of production and process establishment. Through this organization, the satisfaction 
of the stakeholders increases the marketability of the series and this offers an opportunity for 
future development and market. There are different clients that are interested in the processes of 
clinical trials. Agile methodology ensures that there is transparency and the stakeholders are 
involved in all the processes of the development and the establishment of the appropriate 
research processes.  
A research was done by Mahadevan, Kettinger, & Meservy (2015) on the effectiveness of 
agile technology established that the methodology is salient in the early predictions of the 
appropriate delivery periods. The methodology uses a time boxed and fixed schedule sprints to 
come up with an organized process of how the deliveries can be made more effective. The agile 
methodology seeks to create better operational effectiveness. The predictability of the results is 
one of the most important aspects of the operations. The prediction is ensured through the 
establishment of the application of beta test which is a software used specifically for the 
23 
APPLYING THE AGILE MECHANISM IN THE CLINICAL TRIALS DOMAIN 
predictions of the processes. The predictions are done earlier so that there can be planned 
operations to create a sufficient business value. The operations of the processes as established by 
the agile methodology focus on the early predictions for the correction processes to be done 
easily.  
The research done by Flora & Chanda (2014)established that agile methodology allows 
the clients to determine the features and the processes to be used in the project management. This 
allowance is very relevant to the processes of clinical trials since it is from these trials that the 
processes can be determined where the needs of the clients can be understood. Agile 
methodology insists on the specifications of the clients because it is through this establishment 
that the quality of the tests and productions can be realized. Organizations need to ensure that 
they create a strong business value. The value of the business is established when there is 
adherence to the requirements of the clients. The focus of the methodology is on the users and 
not the operations of the organizations. Because of the flexibility of the technology, it becomes 
easy for the users to effectively change the required steps and therefore, ensuring the quality of 
the processes involved.  
Agile methodology and quality improvement 
The information put forth by Rauchenberger, Little & Montana (2013) opined that agile 
methodology allows for handling bigger projects in smaller steps. The projects are broken down 
into smaller operational units which can be easily managed by the processes to be used. The 
projects teams can focus on the aspects of the project that guides the direction of project 
completion. Because the mistakes can be found early in the project processes, it becomes easy 
for corrections to be made. The project teams can focus on the iterations and this improves the 
focus of the development and the operations hence ensuring that there is a high degree of 
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customer satisfaction. The cost of production, the schedules of operations, the scope and 
predictability of operations can be dealt with in time hence improving the effectiveness of the 
technologies to be used. Rauchenberger, Little & Montana (2013) further added that the 
operations of the agile methodology are crucial in the development of the processes and this 
allows for better focus on an iteration. The steps play a crucial role in the establishment of the 
processes. When these steps are considered, the agile methodology ensures that the objectives 
are achieved in a more organized way which focuses more on the business operations.  
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Research methodology 
The research methods are involved in the processes that the researcher took to handle the 
research process. The methodology process informed the researcher the steps which that were 
necessary towards reaching the desired goals of the research.  
Research Worldview 
The structural thinking approach was the most appropriate research method used in the 
process. The structural thinking approach involves a phenomenon analysis with the hope of 
creating an understanding out of the existing information. The researcher equally focused on the 
constructivism mature of worldview in the process of handling the research. Historically, the use 
of waterfall technology has been widely spread. Agile technology has not been fully embraced 
and the clinical domains are not conclusively using in their trials. The processes involved in the 
constructivism approach involve the application of proper systems that can be used to create an 
understanding of the subject matter. The research works, and development is crucial for the 
establishment of a new knowledge. The constructivism worldview approach intends to establish 
an understanding from a nonexistent information. The researcher seeks to create a new 
knowledge both from the research works done in the past and the information received from the 
respondents used for the study. The research was done under the assumption that the healthcare 
organizations were not aware of the effectiveness of the agile methodology and the researcher 
was trying to establish the knowledge for the first time.  
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Research design 
Being that the research does not consider quantities for the analysis processes, it becomes 
easy for the researcher to establish the procedures and the processes that would be appropriate in 
the process of analysis. The nature of the research requires a deep and conclusive analysis of the 
information gathered. To ensure that this is possible, the researcher used the primary qualitative 
research process that engaged the respondents in a more direct manner. The researcher required 
the proper establishment of quality information. The topic of research needed deep analysis. The 
information required open discussions from the respondents and the experts that understood the 
subject matter in a deeper way. From this consideration, the researcher settled for the qualitative 
research methods as a means of data collection.  
Research strategy 
The topic of study needed deep analysis. The researcher used several resources in coming up 
with conclusive information about the effectiveness of using the agile methodology in clinical 
trials. With this focus, the literature review focused on the direct information from a couple of 
researchers where the information required proper capturing for analysis. The researcher equally 
sought to the use of qualitative research methods where the information to be used was linked to 
the understanding of the respondents. The researcher then used the information from the 
literature review to complement the findings from the respondents. The responses were first 
compared for similarities and disparities. In the process of research handling, there were chances 
that certain gaps could not be filled during the research process. The resources used in the 
literature review process were not sufficient to address all the questions that were raised by the 
research. The researcher depended on the respondents through the research processes to fill the 
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gaps that were created by the study. Through this comparison, the desired research quality was 
effectively established.  
Research Population 
Agile methodology technique is an area that has not received a deep attention. The researcher 
needed respondents with good knowledge on the topic. Because it was not easy to tell the level 
of knowledge of the respondents on the subject matter, the researcher resorted to the use of a few 
respondents that understood the clinical trials domains and the natures of the technology that can 
be appropriate for them. The researcher used IT professionals in the healthcare organizations to 
participate in the research process. The researcher equally selected a few clinical officers who 
have had years of experience in clinical processes. This combination was necessary for 
understanding the most commonly used methodologies and the most appropriate ones that could 
be used. The selection process was done randomly.  
Research Sample 
There are several healthcare organizations that could be approached. The researcher minimized 
the use of resources so that only a few people could be used for the sake of the volume of the 
study and the resources that could be used in the process. The researcher settled on 
22respondents who would be appropriate in handling the research process. Equally, the 
researcher selected 10 quality questions that could be easily handled by the researchers so that 
the quality of the research could be maintained. At the same time, the researcher needed to 
ensure that all the areas of the researcher were covered so that the chances of gap development 
could be reduced.  
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Data collection Methods 
The data collection method followed the pattern of the research design developed for the study. 
For the data collection, the use of structured questions was appropriate. The selected respondents 
were given the questions survey via email, so they could prepare for the responses in time. The 
healthcare organizations are among the busiest organization in the world. The professional 
selected for the research process was hard to find because of their work schedules. The 
researcher equally depended on the literature review for the establishment of data reality for 
effective conclusions.  
Data Analysis Method 
Because of the schedule of the research, it was necessary that some of the mails were saved for 
future reference. The researcher could not remember all the responses put forth by the 
respondents and for this reason, the researcher was forced to record the responses with the 
permission of the respondents. The mails were useful for the period of the research process and 
after the research was completed, the researcher was compelled to do away with them for the 
purposes of security and safety of the organizational operations. Equally, the researcher used 
tables and charts to come up with figures in the representation of the general opinions of the 
research works. The researcher came up with certain themes under which the responses of the 
respondents were to be grouped. These themes were represented in tabular forms and charts so 
that the quality of the research could not be lost.  
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RESULTS AND FINDINGS 
Q1: How many years of clinical trial experience you have?  
All the respondents gave their thoughts on the needs of this question. The respondents selected 
were people who had been in the clinical trial for a couple of years. 15 respondents confirmed 
that they have been in the clinical trial professions for one to give years. The number of the 
respondents in this category constituted 68.18% of the total respondents. Six respondents were 
between six to ten years of experience and this constituted 27.27% of the respondents and only 
one respondent had an experience of above ten years. The results are shown in the graph and the 
table below.  
 
Graph 1 
 
Table 1 
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Q2: How many years of agile developments experience you have? 
The second question was based on the understanding of the respondents on the experience on the 
application of agile technology in clinical trials. From this question, five respondents confirmed 
that they have no experience with the use of the agile methodology in clinical trials. These 
respondents had never used the technology in their lives before since they started their clinical 
trial practices. The respondents that had never used the agile methodology in clinical trials 
constituted 22.73% of the total respondents. 17 respondents confirmed that they have used the 
agile methodology for at least one year in their experiences with clinical trials. This percentage 
constituted 77.27% of the total respondents used for the study. The representations of the results 
above are expressed in the graph two and table two below.  
 
 
Graph 2 
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Table 2 
 
Q3: What is the nature of project management methodology used in your organization 
today, specifically for clinical trial projects? 
This question tested on the nature of technologies used by different organizations in their 
processes of project management. Eight respondents, who constituted 36.36% confirmed that 
they use the agile methodology as their project management methodology. Three respondents 
which constitute 13.64% confirmed that their organizations use waterfall methodology as a 
method of project management. The remaining respondents used a hybrid methodology which is 
a combination of both agile and waterfall methodologies as their selected technologies in project 
management. The results of this question are presented in graph 3 and table 3 below 
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Graph 3 
 
Table 3 
 
Q4: How would you following reason to opt for agile methodology in the clinical trial? 
This question as specific on the expectations of the respondents and how they planned to use the 
agile methodology in the project management processes. The question as closed where the 
respondents were only supposed to say whether they agree or not. Three respondents skipped this 
question and this means that only 19 respondents were in a position to respond to the questions 
effectively and completely. The question tested on the role of agile methodology in changing 
requirements and changing technology, the short development cycle, proof of concept upfront 
and how agile methodology could add value on the final product delivery in the clinical trials. 
The respondents reacted to the claims evenly and the results are tabulated in table 4 below. The 
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graphical representation is equally done on the graph 4 below. 
 
Graph 4 
 
Table 4 
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Q5: For how long has the organization used the above project management methodology in 
the clinical trial domain? 
This question tested on the application of the agile methodology in the organizations today. The 
question targeted the application of agile methodology in project management in different 
organizations. One respondent skipped the question and only 21 respondents were in a position 
to respond to the requirements of the question appropriately. Two respondents confirmed that 
they have used agile technology for less than six months. The respondents constituted 9.52 
percent of the total respondents. Six respondents, which constituted 28.57% of the total 
respondents, confirmed that they have used the methodology for between six months to one year. 
Nine respondents, which made a total percentage contribution of 42.86% of the total respondents 
confirmed that they had used the methodology for more than two years and for a maximum of 
five years. Four respondents confirmed to have used the methodology for not less than three 
years. This made about 19% of the total respondents used in the study. The tabulated results are 
shown in table 5below. The graphical representation is equally shown in graph 5 below.  
 
Graph 5 
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Table 5 
 
Q6: How likely is the agile adoption in the clinical environment going to affect the following 
factors? 
1. Project Outcome  
2. Timeline  
3. Cost/ Budget 
4. Stakeholder Management  
5. Project Risks 
The question tested on the effects of agile technology on the different operational units of project 
management. The respondents were supposed to give their views on each operational unit. The 
highest number of respondents agreed that project management processes can be affected by 
different managerial units. The agile methodology has a role to be played in each managerial unit 
and the effects of these considerations could be positive. 44% percent of the respondents 
acknowledged that agile methodology would affect project outcome. 47% of the respondents 
acknowledged that agile methodology would affect the timelines of the project managements, 
52% of the respondents confirmed that the technology would affect the budgeting of the projects, 
project risks and stakeholder management would be affected equally as confirmed by 42% of the 
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respondents. Three respondents skipped the question as 19 out of the 22 respondents gave their 
different views on the agile methodology and the project management units. Table 6 shows the 
detailed response and graph 6 gives an illustration of the responses based on the data collected on 
this question.  
 
Graph 6 
 
Table 6 
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Q7: While implementing the agile method in clinical trial projects in your organization, 
what were challenges in training workforce? 
All the respondents responded to this question. 13 respondents cited lack of skills to be the main 
challenge affecting the implementation of the agile methodology. This response constituted 
59.09% of the total respondents. 12 respondents cited the cost of implementing an agile 
methodology as the major challenge facing the implementation process. The respondents 
constituted 54.55% of the total respondents. 45% of the respondents cited data insufficiency as 
the major problem affecting the implementation of the agile methodology. Table 7 and graph 7 
below illustrate the results of the question.  
 
Graph 7 
 
Table 7 
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Q8: How did you tackle the above challenges while implementing the agile method in 
clinical trial projects in your organization? 
73% of the respondent said that they a hired agile coach to help with the implementation of the 
agile methodology. The 73% was a total of 16 respondents. All the respondents were 
comfortable with responding to this question. Ten respondents who constituted 45% of the total 
sample used in house projects as a means to maneuver through the challenges facing the 
implementation of the technology. Seven respondents confirmed that they used study groups to 
tackle the accompanying challenges in the implementation process. The table 8 and graph 8 
below illustrate the response in this section.  
 
Graph 8 
 
Table 8 
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Q9: What are the challenges do you see in implementing the agile method in clinical trial 
projects? 
All the respondents gave their views on this subject. Nine respondents cited that historical trends 
could be a challenge in the implementation process. 16 respondents cited the FDA regulations to 
be a major problem in the implementation process. 12 respondents were of the opinion that the 
transition period of the implementation would be a challenge in the process. Nine respondents 
feared stakeholders push back as a means of reducing the chances of implementing the 
technology. Table 9 and graph 9 illustrates the responses gathered on this question.  
 
Graph 9 
 
Table 9 
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Q10: What is the maturity level of agile implementation in clinical trial projects? 
45.45% of the total respondents confirmed that agile methodology implementation process is on 
the medium level of implementation. 40.91% confirmed that the implementation phase of the 
agile methodology is still on the initial stages and 13.64% of the total respondents believed the 
implementation process of the methodology was at the highest stage. From the results, only three 
out of the 22 respondents confirmed that the implementation of the technology is on a high level. 
Table 10 and graph 20 illustrates responses received on this question.  
 
Graph 10  
 
Table 10 
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Summary of the findings 
In summary, the research questions were specific to the use of the agile methodology in 
clinical trials and drug development. The research questions were systematic. The questions first 
intended to understand the nature of the respondents from the number of years that they have 
been working in the organizations. From the number of years, the research questions narrowed 
down to the number of years that the respondents had in experience with the application of the 
agile methodology. This understanding was salient in establishing a standard of research. The 
research questions then narrowed further to the application of the agile methodology in the 
specific organizations. The questions tested on the specific applications of the technology, the 
challenges facing its full implementation and the future of application in the development of 
clinical trials.  
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Conclusion  
Agile methodology is appropriate in the clinical trials domain. The clinical processes 
require consistency and good quality in the development. The tracking processes should support 
the desired quality of the end product. From the research, healthcare and pharmaceutical 
organizations have been constantly dependent on the traditional means of making the trials. The 
waterfall technology has been used directly and consistently in the process and through this 
understanding; it has been hard for the pharmaceutical organizations to keep track of the 
processes of the drug developments. The waterfall methodology is not very flexible. The 
methodology does not support a systematic review of the drug development processes. The 
mistakes that are made at one point must affect the entire process and since the correction 
mechanisms cannot be effectively established, the qualities of the trials are lowered.  
The research established the salience of the clinical trials and the application of the agile 
methodology in the process. The advantages of the application of the agile methodology are 
more than those of the traditional systems. The time of operation, the cost of working on the 
clinical trials, the quality of the end products and the ease in making corrections when there is 
need prove the need of the agile methodology in the clinical trials. The research questions were 
specific in getting firsthand information from different professionals on the need for agile 
methodology in the clinical trials. Through the questions, the salience of the methodology was 
established and the gaps that currently exist in the clinical trials filled.  
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Recommendations for future study  
The research considered the need for agile methodology in clinical trials. The researcher 
focused on the advantages and the positive contributions of the methodology on clinical trials. 
The agile methodology has disadvantages or the limitations of its application. For future research 
study, the disadvantages that are aligned with the methodology should be included. The clinical 
trials need to be done in perfection and with the knowledge of the challenges; it would be easy 
for the processes to be improved and the qualities to be effectively established.  
Secondly, from the research development, the application of agile methodology in 
clinical trials was the focus. The results of the interviews indicate that most of the companies 
dealing with the pharmaceutical developments apply both agile and waterfall methodologies. The 
effectiveness of the mixed methods should be compared with the application of the agile 
methodology for appropriate implementation. Future research should the indication of the 
organizational advantage when the only agile methodology is employed for the clinical trials in 
the pharmaceutical companies. 
The research focused on establishing the advantages of applying the agile methodology in 
clinical trials. From the literature review and the results, several advantages were drawn. The 
research did not cover the reliability of the methodology. Future research should consider 
addressing the reliability of the agile methodology alongside the advantages. The application of 
the agile methodology is dependent on both the advantages and the reliability of the technology. 
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